The relevance of glucose counterregulatory systems to patients with insulin-dependent diabetes mellitus

Endocr Rev. 1986 May;7(2):131-9. doi: 10.1210/edrv-7-2-131.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Adrenergic beta-Antagonists / adverse effects
  • Adrenergic beta-Antagonists / therapeutic use
  • Autonomic Nervous System Diseases / physiopathology
  • Blood Glucose / physiology*
  • Brain / physiopathology
  • Chromaffin System / physiopathology
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetes Mellitus, Type 1 / physiopathology*
  • Diabetic Ketoacidosis / etiology
  • Diabetic Neuropathies / physiopathology
  • Epinephrine / physiology
  • Forecasting
  • Glucagon / physiology
  • Growth Hormone / physiology
  • Humans
  • Hydrocortisone / physiology
  • Hyperglycemia / etiology
  • Hypoglycemia / chemically induced
  • Hypoglycemia / etiology
  • Insulin / adverse effects
  • Insulin / physiology
  • Insulin / therapeutic use
  • Stress, Physiological / complications
  • Sympathetic Nervous System / physiopathology

Substances

  • Adrenergic beta-Antagonists
  • Blood Glucose
  • Insulin
  • Growth Hormone
  • Glucagon
  • Hydrocortisone
  • Epinephrine